at 6-week and 1-year follow-up examinations , there was no longer a statistically significant difference in the incidence of neurologic abnormalities between the two therapy groups , but the incidence of hearing impairment in one or both ears was higher in the cefuroxime ( 18 % ) than in the ceftriaxone ( 11 % ) treatment group .
C0018772
hearing impairment
C0013443
ears